Ludwig Oncology Unit, Austin Health, Studley Road, Heidelberg, Victoria 3084, Australia.
Nat Rev Cancer. 2013 Sep;13(9):663-73. doi: 10.1038/nrc3559. Epub 2013 Aug 16.
The ERBB family of receptor tyrosine kinases has a central role in the tumorigenesis of many types of solid tumour. Various therapeutics targeting these receptors have been approved for the treatment of several cancers. Considerable preclinical data have shown that the administration of two inhibitors against an individual ERBB family member--particularly epidermal growth factor receptor (EGFR) or ERBB2--leads to markedly higher antitumour activity than the administration of single agents. This Opinion article describes the preclinical and clinical performance of these dual-targeting approaches, discusses the key mechanisms that mediate their increased efficacy and highlights areas for ongoing investigation.
表皮生长因子受体家族（ERBB）的受体酪氨酸激酶在多种实体肿瘤的发生中起着核心作用。针对这些受体的各种治疗方法已被批准用于治疗多种癌症。大量临床前数据表明，联合使用两种针对单个 ERBB 家族成员（特别是表皮生长因子受体 [EGFR] 或 ERBB2]）的抑制剂比单独使用单一药物具有更高的抗肿瘤活性。本文观点描述了这些双靶向方法的临床前和临床表现，讨论了介导其增效作用的关键机制，并强调了正在研究的领域。
